Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Benchmarks provide a reference point to gauge portfolio performance and risk. This intro explains how comparing returns against a relevant benchmark clarifies decisions and helps align goals.
22,975 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
As AI expands, the biggest upside may come from the hyperscalers funding the cloud and data centers behind the scenes...
A high-stakes portfolio shuffle by a famed activist investor grabbed headlines. This piece breaks down what happened,...
A single year's price move and a wave of AI demand have rewritten the memory market narrative. This article explains ...
The quantum race isn’t only about qubits. Behind every breakthrough is a critical, unglamorous layer of infrastructur...
A broad pullback in software stocks has created compelling opportunities for patient investors. Here are two names wi...
Two popular aerospace ETFs pick up very different signals from the sky. This guide explains why cost, exposure, and c...
A biotech insider trade draws attention after an FDA setback. This article unpacks the CFO's $720k stock sale at Disc...
One fund dramatically cut its exposure to a China education stock, committing to no EDU shares while preserving a hef...
Insider sales by a bank CEO can raise questions. This article breaks down what a move like 'live bancshares sells ano...
As markets navigated a cautious session, Sunrun’s new framework with Tesla and Renew Home pushed renewable energy equ...
Sable Offshore stock tanked over the last year as oil markets swung and investors weighed long-term offshore exposure...